文献速递血液净化与透析慢性肾脏病

透析患者使用磷结合剂蔗糖氢氧化氧铁对体内钙化蛋白颗粒、炎症及血管细胞的影响

Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

该研究为随机对照交叉研究的二次分析,在28例血液透析患者中比较2周停用磷结合剂与高剂量(2000 mg/天)和低剂量(250 mg/天)蔗糖氢氧化氧铁(SO)治疗对血清钙化蛋白颗粒(CPP)、炎症因子及人血管细胞体外实验的影响。高剂量SO较停药期降低原发性和继发性CPP水平,并减少多种细胞因子/趋化因子,患者血清促钙化和促炎效应减弱。

要点

  • 高剂量SO较停药期降低原发性CPP 62%(95%CI -76至-44,P<.0001)和继发性CPP 38%(95%CI -62至-0.14,P<.001)。
  • 高剂量SO使14种血浆细胞因子/趋化因子中9种显著下降,IL-6和IL-8持续降低。
  • SO治疗患者血清体外促血管钙化和促炎效应较停药期减弱,去除CPP组分可改善该效应。

核心结论

  • 高剂量SO降低透析患者体内CPP形成,并产生体外促钙化和促炎效应减弱的血清。

研究设计与样本

  • 随机对照交叉研究的二次分析,纳入28例血液透析患者,比较2周停用磷结合剂与高剂量(2000 mg/天)和低剂量(250 mg/天)SO治疗。

主要发现

  • 队列中男性占75%,年龄62±12岁;高剂量SO较停药期降低原发性CPP 62%(95%CI -76至-44,P<.0001)和继发性CPP 38%(95%CI -62至-0.14,P<.001)。
  • 高剂量SO使14种血浆细胞因子/趋化因子中9种显著下降,IL-6和IL-8持续降低。
  • 人主动脉平滑肌细胞(HASMC)和冠状动脉内皮细胞(HCAEC)暴露于SO治疗患者血清后,较停药期血清钙化和活化标志物(IL-6、IL-8和血管细胞黏附蛋白1)减少。
  • 去除患者血清中含CPP组分可改善血清诱导的HASMC钙化和HCAEC活化,该效应在慢性肾脏病患者独立队列中得到验证。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Calciprotein particles (CPPs), colloidal mineral-protein nanoparticles, have emerged as potential mediators of phosphate toxicity in dialysis patients, with putative links to vascular calcification, endothelial dysfunction and inflammation. We hypothesized that phosphate binder therapy with sucroferric oxyhydroxide (SO) would reduce endogenous CPP levels and attenuate pro-calcific and pro-inflammatory effects of patient serum towards human vascular cells in vitro. METHODS: This secondary analysis of a randomised controlled crossover study compared the effect of 2-week phosphate binder washout with high-dose (2000 mg/day) and low-dose (250 mg/day) SO therapy in 28 haemodialysis patients on serum CPP levels, inflammatory cytokine/chemokine arrays and human aortic smooth muscle cell (HASMC) and coronary artery endothelial cell (HCAEC) bioassays. RESULTS: In our cohort (75% male, 62 ± 12 years) high-dose SO reduced primary (amorphous) and secondary (crystalline) CPP levels {-62% [95% confidence interval (CI) -76 to -44], P < .0001 and -38% [-62 to -0.14], P < .001, respectively} compared with washout. Nine of 14 plasma cytokines/chemokines significantly decreased with high-dose SO, with consistent reductions in interleukin-6 (IL-6) and IL-8. Exposure of HASMC and HCAEC cultures to serum of SO-treated patients reduced calcification and markers of activation (IL-6, IL-8 and vascular cell adhesion protein 1) compared with washout. Serum-induced HASMC calcification and HCAEC activation was ameliorated by removal of the CPP-containing fraction from patient sera. Effects of CPP removal were confirmed in an independent cohort of chronic kidney disease patients. CONCLUSIONS: High-dose SO reduced endogenous CPP formation in dialysis patients and yielded serum with attenuated pro-calcific and inflammatory effects in vitro.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Thiem U, Hewitson TD, Toussaint ND, et al. Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells. Nephrol Dial Transplant. 2023. PMID: 36107466. doi:10.1093/ndt/gfac271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。